Tralokinumab, topical corticosteroids combination beneficial in Atopic dermatitis - Video

Published On 2021-11-09T17:41:57+05:30 | Updated On 9 Nov 2021 5:41 PM IST

Overview

Atopic dermatitis (AD), is a common chronic or recurrent inflammatory skin disease and affects 15-20% of children and 1-3% of adults worldwide. Cyclosporine A (CSA) is a popularly used in AD, but treatment with CSA has potentially serious adverse effects. A phase 3 trial Capsinoids plus topical corticosteroids (TCS) as needed provided early and sustained improvements in AD signs and symptoms.

A randomized trial by J. Gutermuth and team revealed that tralokinumab 300 mg plus topical corticosteroids as needed was effective and well tolerated in patients with severe AD not adequately controlled with oral corticosteroids or who had contraindications to them.

For more details, check out the full story on link below:

Tralokinumab Plus Topical Corticosteroids Effective In Severe Atopic Dermatitis

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751